Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Friedman, M.D.
Vertex Pharmaceuticals Incorporated
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
83 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Linz, Austria
- Facility name not stated
Vienna, Austria
- Facility name not stated
Vienna, Austria
- Facility name not stated
Calgary, Alberta, Canada
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
Winnipeg, Manitoba, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Berlin, Germany
- Facility name not stated
Cologne, Germany
- Facility name not stated
Düsseldorf, Germany
- Facility name not stated
Frankfurt, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Hanover, Germany
- Facility name not stated
Leipzig, Germany
- Facility name not stated
Munich, Germany
- Facility name not stated
Haifa, Israel
- Facility name not stated
Haifa, Israel
- Israel
Jerusalem, Israel
- Facility name not stated
Nazareth, Israel
- Facility name not stated
Petah Tikva, Israel
- Facility name not stated
Tel Litwinsky, Israel
- Facility name not stated
Bialystok, Poland
- Facility name not stated
Czeladź, Poland
- Facility name not stated
Mysłowice, Poland
- Facility name not stated
Wroclaw, Poland
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Phoenix, Arizona, United States
- Facility name not stated
La Jolla, California, United States
- California
Los Angeles, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Sacramento, California, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
San Diego, California, United States
- California
San Francisco, California, United States
- Facility name not stated
Farmington, Connecticut, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2011
- Primary completion
- 31 Jan 2014
- Completion
- 31 Jan 2014
- Last update posted
- 10 Jun 2015
- Registered enrollment
- 239
- Registry id
- NCT01459913
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.